ライフサイエンスコーパス: adenomatous polyposis

1 ch are similar to those observed in familial adenomatous polyposis.

2 is associated with pathogenesis of familial adenomatous polyposis.

3 ng causes of death in patients with familial adenomatous polyposis.

4 t with Apc, are important models of familial adenomatous polyposis.

5 a development in an animal model of familial adenomatous polyposis.

6 n combination in an animal model of familial adenomatous polyposis.

7 pathogenic variants associated with familial adenomatous polyposis.

8 n additional recessive subtype of colorectal adenomatous polyposis.

9 h either drug alone, in adults with familial adenomatous polyposis.

10 m 102 unrelated individuals with unexplained adenomatous polyposis.

11 equently remains unresolved in patients with adenomatous polyposis.

12 sies from IPAA patients with UC and familial adenomatous polyposis.

13 es of hereditary syndromes, such as familial adenomatous polyposis, a cancer predisposition syndrome

14 Patients with familial adenomatous polyposis after pouch surgery (n = 9), indiv

15 rome and the phenotypic features of familial adenomatous polyposis aid significantly in syndrome diag

16 , germline mutation of which causes familial adenomatous polyposis, an autosomal intestinal cancer sy

17 tions affecting NTHL1 predispose carriers to adenomatous polyposis and colorectal cancer, but the com

18 edisposes to a new subtype of BER-associated adenomatous polyposis and CRC.

19 types in a murine model of colon cancer, the adenomatous polyposis (APC) mutant (Apc (716/+)) model.

20 isease progression in patients with familial adenomatous polyposis are unknown.

21 in animals and in patients with the familial adenomatous polyposis by downregulating beta-catenin sig

22 and inherited conditions (Lynch and familial adenomatous polyposis), by changing only 2 tissue-specif

23 The adenomatous polyposis cell (APC) tumor suppressor is a m

24 e conditionally expressed a mutant allele of adenomatous polyposis coli (APC(cKO)) in murine uterine

25 al crypt, augmenting CRC tumorigenesis in an adenomatous polyposis coli (APC(Delta14/+)) mouse model.

26 n on chronic hypoxia-induced PH, we used the adenomatous polyposis coli (Apc(Min/+)) mouse, where red

27 as a binding partner of the tumor suppressor adenomatous polyposis coli (APC) [1]; however, the signi

28 The tumor suppressor Adenomatous polyposis coli (APC) affects the function of

29 induced by the rare inheritance of a mutant adenomatous polyposis coli (Apc) allele.

30 ministering LPA to mice heterozygous for the adenomatous polyposis coli (Apc) allele.

31 contribution of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathoge

32 ested that specific GSK3 substrates, such as adenomatous polyposis coli (APC) and collapsin response

33 wo microtubule plus end-associated proteins, adenomatous polyposis coli (APC) and EB1, providing a po

34 onal and transcriptional mechanisms and that adenomatous polyposis coli (APC) and GSK3beta, which are

35 expression of the gut tumor suppressor gene adenomatous polyposis coli (Apc) and its role in the oli

36 Finally, CBC stem cells deficient in adenomatous polyposis coli (Apc) and Math1 were able to

37 ed by the colorectal cancer tumor suppressor adenomatous polyposis coli (APC) and that KLF4 repressed

38 ther, we find that both the tumor suppressor adenomatous polyposis coli (APC) and the ADP-ribose poly

39 nce microscopy to image the tumor suppressor adenomatous polyposis coli (APC) and the formin mDia1 du

40 firmed an expected loss in the expression of adenomatous polyposis coli (APC) and the transcriptional

41 First, patients with germline mutations in adenomatous polyposis coli (APC) are susceptible to stom

42 polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP

43 As in mammals, loss of adenomatous polyposis coli (APC) causes Drosophila intes

44 Here we find that the tumor suppressor adenomatous polyposis coli (APC) controls microtubule ta

45 C57BL/6J mice carrying the Min allele of Adenomatous polyposis coli (Apc) develop numerous adenom

46 Mutations in adenomatous polyposis coli (APC) disrupt regulation of W

47 As Adenomatous Polyposis Coli (APC) functions in many of th

48 mice bearing a heterozygote mutation in the adenomatous polyposis coli (APC) gene (Apc(Min/+) mice).

49 ted gene-targeted pigs with mutations in the adenomatous polyposis coli (APC) gene (APC) that are ort

50 of these models involve modification of the adenomatous polyposis coli (Apc) gene and are excellent

51 ased in human cells with deficiencies in the adenomatous polyposis coli (APC) gene and in cells stimu

52 We show that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent act

53 Mutations in the adenomatous polyposis coli (APC) gene are associated wit

54 Patients with mutations in the Adenomatous Polyposis Coli (APC) gene are at increased r

55 Somatic mutations of the adenomatous polyposis coli (APC) gene are initiating eve

56 Mutations in the adenomatous polyposis coli (APC) gene are pivotal in col

57 The adenomatous polyposis coli (APC) gene encodes APC tumour

58 Since the Adenomatous Polyposis Coli (APC) gene is mutated in the

59 The Adenomatous Polyposis Coli (APC) gene is mutated in the

60 The adenomatous polyposis coli (APC) gene is mutated within

61 Although beta-catenin and adenomatous polyposis coli (APC) gene mutations are well

62 Adenomatous polyposis coli (APC) gene mutations have bee

63 Mutations in the adenomatous polyposis coli (APC) gene occur in the vast

64 The adenomatous polyposis coli (APC) gene plays, among other

65 The adenomatous polyposis coli (APC) gene product is mutated

66 letion in mice with inactivating mutation of adenomatous polyposis coli (APC) gene reduces intestinal

67 ssf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate inte

68 ization of beta-catenin or defective for the adenomatous polyposis coli (APC) gene to reinvestigated

69 n the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult b

70 intestinal carcinogenesis is mutation of the adenomatous polyposis coli (APC) gene, which leads to ac

71 requently bear inactivating mutations of the adenomatous polyposis coli (APC) gene, whose product is

72 velop through loss of normal function of the Adenomatous polyposis coli (APC) gene.

73 g, in particular, tumor suppressors TP53 and adenomatous polyposis coli (APC) gene.

74 imiting mutations in human CRC occurs in the adenomatous polyposis coli (APC) gene.

75 omas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene.

76 nt in mice with heterozygous mutation in the adenomatous polyposis coli (APC) gene.

77 cancer cases due to somatic mutations in the adenomatous polyposis coli (APC) gene.

78 criptional and epigenetic changes induced by adenomatous polyposis coli (Apc) inactivation in intesti

79 Wnt/beta-catenin pathway signaling following adenomatous polyposis coli (APC) inactivation.

80 Mutations in the tumor suppressor adenomatous polyposis coli (APC) initiate most colon can

81 The tumor suppressor adenomatous polyposis coli (APC) is a crucial regulator

82 ncluding the brain, and the tumor suppressor adenomatous polyposis coli (APC) is a key negative regul

83 Adenomatous polyposis coli (APC) is a large multidomain

84 Adenomatous polyposis coli (APC) is a microtubule plus-e

85 The tumor suppressor Adenomatous polyposis coli (APC) is a negative regulator

86 Mutational inactivation of adenomatous polyposis coli (APC) is an early event in co

87 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

88 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

89 ASE of adenomatous polyposis coli (APC) is associated with path

90 Adenomatous polyposis coli (APC) is best known for its c

91 Mutation of the tumor suppressor adenomatous polyposis coli (APC) is considered an initia

92 The tumor suppressor adenomatous polyposis coli (APC) is frequently mutated i

93 The tumor suppressor adenomatous polyposis coli (APC) is implicated in regula

94 The tumor suppressor protein adenomatous polyposis coli (APC) is multifunctional - it

95 Adenomatous polyposis coli (APC) is mutated in colon can

96 Adenomatous polyposis coli (APC) is one such MAP with a

97 Loss of tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

98 aling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

99 ore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by

100 Today, the tumor suppressor adenomatous polyposis coli (APC) may have the same compl

101 te that intestinal epithelial suppression of adenomatous polyposis coli (Apc) mitigates RIGS lethalit

102 Here, we show that adenomatous polyposis coli (APC) modulates microtubule (

103 ects of daily oral administration of HFCS in adenomatous polyposis coli (APC) mutant mice, which are

104 esis that initiation of colorectal cancer by adenomatous polyposis coli (APC) mutation is mediated by

105 Adenomatous polyposis coli (APC) mutation is the most co

106 gastric cancer cells even in the presence of adenomatous polyposis coli (Apc) mutation.

107 Adenomatous polyposis coli (APC) mutations are linked to

108 In this study, we show that adenomatous polyposis coli (APC) mutations found in huma

109 nt/beta-catenin pathway activation caused by adenomatous polyposis coli (APC) mutations occurs in app

110 The tumor suppressor Adenomatous polyposis coli (APC) negatively regulates Wn

111 Depletion of the tumor suppressors adenomatous polyposis coli (APC) or Axin dramatically in

112 (CRCs), an initiating mutation occurs in the adenomatous polyposis coli (APC) or beta-catenin gene, a

113 n that have been associated with loss of the adenomatous polyposis coli (APC) or constitutive activat

114 d glycogen synthase kinase 3beta (GSK-3beta)/adenomatous polyposis coli (APC) pathways.

115 The tumor suppressor Adenomatous polyposis coli (APC) plays a key role in reg

116 nestin expressing NeuN positive neurons and adenomatous polyposis coli (APC) positive mature oligode

117 ver beta-catenin/E-cadherin and beta-catenin/adenomatous polyposis coli (APC) PPIs.

118 ibition of GSK-3beta and accumulation of the adenomatous polyposis coli (APC) protein at the plus end

119 ere, we report that the expression status of adenomatous polyposis coli (APC) protein determines the

120 The adenomatous polyposis coli (APC) protein functions as a

121 Adenomatous polyposis coli (APC) protein is a large tumo

122 CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabili

123 Fap1 also interacts with the adenomatous polyposis coli (Apc) protein, but the functi

124 inked to deficiencies in mismatch repair and adenomatous polyposis coli (APC) proteins, diet, inflamm

125 ing a knockout allele in the gatekeeper gene Adenomatous polyposis coli (Apc) recapitulates familial

126 The tumor suppressor protein adenomatous polyposis coli (APC) regulates cell protrusi

127 Adenomatous polyposis coli (APC) regulates the activity

128 is functionally important for cell migration.Adenomatous polyposis coli (APC) regulates the localizat

129 gene targeting in mice, we demonstrate that adenomatous polyposis coli (APC) serves an essential fun

130 ne such pathway the tumor-suppressor protein adenomatous polyposis coli (APC) targets RNAs to cell pr

131 ting factor-responsive cells were defined by adenomatous polyposis coli (APC) time-of-flight mass cyt

132 Binding of adenomatous polyposis coli (APC) to the microtubule plus

133 In turn, KIF17 participates in localizing adenomatous polyposis coli (APC) to the plus ends of a s

134 The adenomatous polyposis coli (APC) tumor suppressor forms

135 Acquired or inherited mutations in the adenomatous polyposis coli (APC) tumor suppressor gene a

136 The adenomatous polyposis coli (APC) tumor suppressor gene e

137 The Adenomatous Polyposis Coli (APC) tumor suppressor gene i

138 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene i

139 cells lines with truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor gene t

140 Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is fre

141 The adenomatous polyposis coli (APC) tumor suppressor is ina

142 The adenomatous polyposis coli (Apc) tumor suppressor is inv

143 ce with IEC-specific allelic deletion of the adenomatous polyposis coli (Apc) tumor suppressor locus,

144 The adenomatous polyposis coli (APC) tumor suppressor protei

145 atase 2A (PP2A) and must be protected by the adenomatous polyposis coli (APC) tumor suppressor protei

146 Mutation of the adenomatous polyposis coli (APC) tumor suppressor stabil

147 rcinomas contain truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor, a neg

148 in signaling is negatively controlled by the adenomatous polyposis coli (APC) tumor suppressor, which

149 calculating the in vivo mutation rate of the adenomatous polyposis coli (APC) tumor-suppressor gene i

150 ollows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and a

151 RNAs in the granules associate with the adenomatous polyposis coli (APC) tumour suppressor and t

152 Mutations in the adenomatous polyposis coli (APC) tumour suppressor are t

153 Mutations in Adenomatous polyposis coli (APC) underlie familial adeno

154 Mutations in adenomatous polyposis coli (APC) underlie the earliest s

155 In this study, the tumor suppressor protein adenomatous polyposis coli (APC) was found to be importa

156 We found that the tumor suppressor adenomatous polyposis coli (APC) was required for microt

157 These mice were crossed with adenomatous polyposis coli (Apc)(min/+) mice, or given a

158 ne the genetic relationship between MPC1 and Adenomatous polyposis coli (APC), a key tumor suppressor

159 Inactivating mutations within adenomatous polyposis coli (APC), a negative regulator o

160 Adenomatous polyposis coli (APC), a protein with both tu

161 approaches suggest that the tumor suppressor adenomatous polyposis coli (APC), a regulator of Wnt sig

162 Adenomatous polyposis coli (APC), a tumor suppressor com

163 Adenomatous polyposis coli (Apc), a tumor suppressor gen

164 Adenomatous polyposis coli (APC), a tumor suppressor gen

165 Specific site of CpG islands of adenomatous polyposis coli (APC), a well studied tumor s

166 The tumor suppressor adenomatous polyposis coli (APC), an essential negative

167 atenin destruction complex components Axin1, adenomatous polyposis coli (APC), and GSK3beta were also

168 forms a complex with axin (axis inhibitor), adenomatous polyposis coli (APC), casein kinase 1alpha (

169 Together with its direct binding partner adenomatous polyposis coli (APC), EB1 can stabilize micr

170 Mutations in known driver genes [e.g., adenomatous polyposis coli (APC), KRAS, or PIK3CA] found

171 Individual crypt adenomatous polyposis coli (APC), p53, K-RAS, and 17p lo

172 in acromegaly patients induced colon p53 and adenomatous polyposis coli (APC), reversing progrowth GH

173 e designed against beta-catenin (Ctnnb1) and adenomatous polyposis coli (Apc), two commonly mutated g

174 ical Wnt signaling by targeting the gene for Adenomatous Polyposis Coli (Apc), which controls Wnt sig

175 e, we show that the tumor suppressor protein adenomatous polyposis coli (APC), which is a known MT-as

176 Expression of eIF6 in adenomatous polyposis coli (APC)-mutant colon cancer cel

177 ulation and epithelial over-proliferation in Adenomatous polyposis coli (APC)-mutated intestine.

178 o develop colitis-associated and spontaneous adenomatous polyposis coli (APC)-related tumors of the i

179 iously disclosed the discovery of truncating adenomatous polyposis coli (APC)-selective inhibitor 1 (

180 to the inactivation of the tumor suppressor adenomatous polyposis coli (APC).

181 by aberrant function of the tumor suppressor Adenomatous polyposis coli (Apc).

182 P), Skp1, transducin beta-like 1 (TBL1), and adenomatous polyposis coli (APC).

183 runcating mutations in the tumor suppressor, adenomatous polyposis coli (APC).

184 RC) through mutation of the tumor suppressor Adenomatous Polyposis Coli (APC).

185 glycogen synthase kinase-3beta, axin-1, and adenomatous polyposis coli (APC).

186 ation suppresses beta-catenin activity in an adenomatous polyposis coli (APC)/glycogen synthase kinas

187 s; and suppresses colonic polyp formation in adenomatous polyposis coli (APC)min/+ mice.

188 We analyzed adenomatous polyposis coli (Apc)min/+/Sigirr-/- mice for

189 py, FRAP, live cell imaging, and a mutant of Adenomatous polyposis coli (APC-m4) defective in actin n

190 Arm is targeted for proteolysis by the Axin/Adenomatous polyposis coli (Apc1 and Apc2)/Zeste-white 3

191 V integration site family (WNT)/beta-catenin/adenomatous polyposis coli (CTNNB1/APC) pathway has been

192 alignancies due to inactivating mutations of adenomatous polyposis coli (in colorectal cancer) or act

193 In addition we identified adenomatous polyposis coli 1 (APC1) as an interaction pa

194 Germline specific overexpression of Adenomatous Polyposis Coli 2 (APC2) rescued GSC loss in

195 sly in germ cells for proper localization of Adenomatous polyposis coli 2 and E-cadherin at the hub-G

196 vilVEGF1 mice were bred to Min mice (adenomatous polyposis coli [APC] +/-).

197 ation of the centrosomal proteins Ninein and adenomatous polyposis coli abolished this bias.

198 tive regulators of beta-catenin, such as the adenomatous polyposis coli and Axin tumor suppressor pro

199 G-protein signaling (RGS) domain that binds adenomatous polyposis coli and Galpha subunits, thereby

200 atenin and the destruction complex component adenomatous polyposis coli at a similar SLS motif to the

201 Mutations in the adenomatous polyposis coli gene (Apc) are a major driver

202 as associated with reduced expression of the adenomatous polyposis coli gene (APC).

203 iation domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in his

204 Mice carrying and non-sense mutation in Adenomatous polyposis coli gene at site R850, which desi

205 eficient mice carrying the Min allele of the adenomatous polyposis coli gene.

206 and compared to control mice carry wildtype Adenomatous polyposis coli gene.

207 t is caused by inactivating mutations in the Adenomatous polyposis coli gene.

208 olocalizes with the tumor suppressor protein adenomatous polyposis coli in the TJs of epithelial cell

209 Crossing Tfam(+/-) mice to the adenomatous polyposis coli multiple intestinal neoplasia

210 Here, we demonstrate that adenomatous polyposis coli mutant APC(Min/+) mice, which

211 RC) harboring functional mutations in either adenomatous polyposis coli or beta-catenin.

212 ling induced by loss of the tumor suppressor adenomatous polyposis coli or casein kinase 1alpha uncov

213 Most information about the roles of the adenomatous polyposis coli protein (APC) and its binding

214 We recently identified adenomatous polyposis coli protein (APC) as a key regula

215 Here we report that the tumour suppressor adenomatous polyposis coli protein (APC) directs the loc

216 We propose that adenomatous polyposis coli protein (APC) is a key coordi

217 have bi-allelic mutations in APC2, encoding adenomatous polyposis coli protein 2.

218 ows that the actin-nucleating ability of the adenomatous polyposis coli protein is required for disas

219 versely, RNAi of the beta-catenin antagonist adenomatous polyposis coli results in the regeneration o

220 W480 cells stably transformed with wild-type adenomatous polyposis coli showed decreased beta-catenin

221 syndrome caused by germline mutations in the adenomatous polyposis coli tumor suppressor gene.

222 he microtubule motor cytoplasmic dynein, the adenomatous polyposis coli tumor suppressor protein (APC

223 The APC gene encodes the adenomatous polyposis coli tumour suppressor protein, ge

224 However, little is known about adenomatous polyposis coli's (APC's) role in the mammali

225 member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g.

226 In the context of APC (adenomatous polyposis coli) deficiency (Apc(Min/+) mice)

227 g in T cell lineages by deletion of the Apc (adenomatous polyposis coli) gene causes spontaneous T ce

228 mutation of the Wnt repressor APC (encoding adenomatous polyposis coli) leads to a state of aberrant

229 that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of bet

230 We had shown that the APC (adenomatous polyposis coli) protein controls localizatio

231 her beta-catenin activation or loss of APC - adenomatous polyposis coli) upon expression of CRE recom

232 Disruption of Apc (adenomatous polyposis coli) within hepatocytes activates

233 ectly targets the tumor suppressor gene APC (adenomatous polyposis coli), thereby affecting Wnt (Wing

234 adenoma growth in the context of mutant Apc (adenomatous polyposis coli).

235 ducin repeat-containing protein 2), and APC (adenomatous polyposis coli).

236 aditionally attributed to mutations in Axin, adenomatous polyposis coli, and beta-catenin that lead t

237 I, IGF2; tumor suppressor candidate 33, N33; adenomatous polyposis coli, APC; mut-L homolog 1, MLH1;

238 a-catenin pathway mutations, such as loss of adenomatous polyposis coli, are insensitive to this nove

239 Because mutations in adenomatous polyposis coli, beta-catenin and other compo

240 -catenin pathway regulatory genes, including adenomatous polyposis coli, GSK3beta, axin 1, beta-caten

241 Inactivation of the tumor suppressor adenomatous polyposis coli, with the resultant activatio

242 e glycogen synthase kinase 3beta (GSK3beta)- adenomatous polyposis coli-axin-mediated degradation pat

243 otubule organization and capture dynamics in adenomatous polyposis coli-deficient radial progenitors.

244 ted signaling and glycogen synthase kinase-3/adenomatous polyposis coli-mediated beta-catenin activat

245 ence in normal intestinal homeostasis and in adenomatous polyposis coli-mediated tumorigenesis.

246 intestinal tumors driven by mutations in the adenomatous polyposis coli/beta-catenin pathway and acti

247 f cell lines even harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

248 ble in cell lines harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

249 erived WNT2 activated canonical signaling in adenomatous polyposis coli/beta-catenin wild-type colon

250 ications of MMVTx for patients with familial adenomatous polyposis (FAP) and the technical feasibilit

251 Patients with familial adenomatous polyposis (FAP) are at markedly increased ri

252 amatically altered for the worse in familial adenomatous polyposis (FAP) because these patients harbo

253 We studied patients with Familial Adenomatous Polyposis (FAP) because they are virtually c

254 identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified

255 tumors often occur in patients with familial adenomatous polyposis (FAP) coli who have germ line muta

256 rative colitis (UC) in 37 patients, familial adenomatous polyposis (FAP) in 12 patients, and colonic

257 of thyroid cancer in patients with Familial adenomatous polyposis (FAP) in a prospective study of th

258 Familial adenomatous polyposis (FAP) is a human cancer syndrome c

259 Familial Adenomatous Polyposis (FAP) is characterized by marked u

260 ial cancer predispositions known as familial adenomatous polyposis (FAP) or Gardner syndrome.

261 rliest colonic tissue alteration in familial adenomatous polyposis (FAP) patients, we present the hyp

262 s after 4-6 months of treatment for familial adenomatous polyposis (FAP) patients.

263 ine mutation of which characterizes familial adenomatous polyposis (FAP), an autosomal intestinal can

264 atous polyposis coli (APC) underlie familial adenomatous polyposis (FAP), an inherited cancer syndrom

265 ive colitis, indeterminate colitis, familial adenomatous polyposis (FAP), and a select group of patie

266 inherited predisposition, including familial adenomatous polyposis (FAP), hereditary nonpolyposis col

267 atorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imag

268 hallmark of many cancers, including familial adenomatous polyposis (FAP)-related desmoid tumors.

269 ccur in up to 21 % of patients with Familial Adenomatous Polyposis (FAP).

270 type 2 (MEN2), Cowden syndrome, and familial adenomatous polyposis (FAP).

271 colorectal polyps in children with familial adenomatous polyposis (FAP).

272 gous to those responsible for human familial adenomatous polyposis (FAP).

273 oter 1B occur in rare families with familial adenomatous polyposis (FAP).

274 to iPSCs derived from patients with familial adenomatous polyposis (FAP-iPSCs) harboring germline mut

275 ative colitis (UC) versus controls (familial adenomatous polyposis [FAP]).

276 rosis, Duchenne Muscular Dystrophy, Familial Adenomatous Polyposis, Hereditary Non-polyposis Colorect

277 h as multiple endocrine neoplasias, familial adenomatous polyposis, hereditary nonpolyposis colon can

278 ive colitis in 73% of the cases and familial adenomatous polyposis in 17%.

279 enomas recovered from patients with familial adenomatous polyposis, including adenomas as small as a

280 Familial adenomatous polyposis is an inherited genetic disease, w

281 and multiple POFLs associated with familial adenomatous polyposis is reviewed.

282 yndromes, including Lynch syndrome, familial adenomatous polyposis, MUTYH-associated polyposis, and c

283 testinal tissues from patients with familial adenomatous polyposis (n = 18) or sessile serrated adeno

284 and normal pouch from patient with familial adenomatous polyposis (n = 6).

285 ately 30% of families affected by colorectal adenomatous polyposis, no germline mutations have been i

286 inically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis.

287 associated with thyroid cancer (eg, familial adenomatous polyposis), or one or more first-degree rela

288 A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can i

289 osely simulates that found in human familial adenomatous polyposis patients.

290 families showed recessive inheritance of the adenomatous polyposis phenotype and progression to CRC i

291 opic expression of APC, but not its familial adenomatous polyposis-related truncation mutant, promine

292 In murine models of familial adenomatous polyposis, specifically the multiple intesti

293 Studies of tumors from human familial adenomatous polyposis, sporadic colon cancer, and mouse

294 In this study, using a human familial adenomatous polyposis syndrome susceptible mouse model,

295 y nonpolyposis colorectal cancer or familial adenomatous polyposis syndromes.

296 ajority of the 30% of patients with familial adenomatous polyposis that do not test positive for muta

297 this trial involving patients with familial adenomatous polyposis, the incidence of disease progress

298 diseases, three females (1.6 %) had familial adenomatous polyposis; three patients (1 male and two fe

299 on-negative Lynch syndrome, 16 with familial adenomatous polyposis, two with constitutional mismatch

300 polyposis coli (APC) gene reduces intestinal adenomatous polyposis via Axin/beta-catenin axis and the